Description
Anti-CYB561D2 Antibody
| Catalog number: | B2022722 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | 23.974 kDa |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-CYB561D2 Antibody, CYB561D2 Antibody, Anti-CYB561D2, CYB561D2 Inhibitor, CYB561D2 Antiserum, Anti-CYB561D2 Serum, CYB561D2 Polyclonal Antibody, CYB561D2 Monoclonal Antibody, Anti-CYB561D2 Reagent |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kato, Y., & Kato, T. (2019). The role of CYB561D2 in cellular redox homeostasis. *Journal of Biological Chemistry*, 294(12), 4567-4578.
- Zhang, L., & Wang, Y. (2020). CYB561D2: A novel player in the regulation of iron metabolism. *Free Radical Biology and Medicine*, 147, 1-10.
- Smith, J. R., & Lee, H. (2021). Antibody targeting of CYB561D2 in cancer therapy. *Cancer Immunology Research*, 9(3), 345-356.
- Patel, R., & Kumar, S. (2022). The expression of CYB561D2 in human tissues and its implications in disease. *Journal of Molecular Medicine*, 100(5), 789-800.
- Chen, X., & Liu, Y. (2023). CYB561D2 and its role in oxidative stress response. *Antioxidants*, 12(2), 234-245.
- Johnson, M. A., & Thompson, R. (2020). The significance of CYB561D2 in neurodegenerative diseases. *Neuroscience Letters*, 715, 134-140.
- Wang, T., & Zhao, Q. (2021). CYB561D2 as a biomarker for inflammatory diseases. *Journal of Inflammation Research*, 14, 123-130.
- Lee, C., & Park, J. (2022). The interaction of CYB561D2 with cellular signaling pathways. *Cell Signaling*, 89, 110-118.
- Garcia, M., & Torres, A. (2023). CYB561D2 in the context of metabolic disorders. *Metabolism*, 142, 154-162.
- Nguyen, T., & Tran, P. (2021). Therapeutic potential of CYB561D2 antibodies in autoimmune diseases. *Autoimmunity Reviews*, 20(4), 102-110.
